Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944951107> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W2944951107 endingPage "22" @default.
- W2944951107 startingPage "15" @default.
- W2944951107 abstract "Efficacy, safety and biotransformation features of any drug are fully revealed during widely using. Therefore, postmarketing studies of the pharmacological properties of drugs are an integral component of pharmacovigilance. The aim of this study was to evaluate the nature and frequency of drugs adverse reactions that have been reported in the post-marketing period, as well as a review of measures taken by foreign regulatory authorities to ensure the safety of use of these drugs. The results of monitoring the drug safety in the post-marketing period used in clinical practice during various time intervals are presented: from several years (atelizumab, daclizumab) to several decades (valproate, retinoids). The review included data from decisions of regulatory authorities, published in 2018. Recommendations from foreign sources on the rational use of drugs, ways to increase the benefit/risk ratio of adverse reactions when using drugs from different therapeutic groups and/or the need for changes in the instructions on their medical use due to changes in the safety profile are considered. These recommendations will be helpful to healthcare professionals, as well as persons authorized for pharmacovigilance by pharmaceutical companies. Particularly, this information may be of interest to rheumatologists, oncologists, neurologists, psychiatrists, as well as other physicians who use atezolizumab, tocilisumab, daclizumab, pomalidomide, valproate sodium and valproic acid, retinoids, clarithromycin, cotrimaxozol, cefalexine, hydroxycarbamide, ritonavir." @default.
- W2944951107 created "2019-05-29" @default.
- W2944951107 creator A5003511699 @default.
- W2944951107 creator A5010363824 @default.
- W2944951107 creator A5015370048 @default.
- W2944951107 creator A5027329850 @default.
- W2944951107 creator A5033713993 @default.
- W2944951107 creator A5034671511 @default.
- W2944951107 creator A5046513164 @default.
- W2944951107 creator A5048153783 @default.
- W2944951107 creator A5054603859 @default.
- W2944951107 date "2019-03-25" @default.
- W2944951107 modified "2023-09-25" @default.
- W2944951107 title "The Adverse Drug Reactions Registered During the Postmarketing Period" @default.
- W2944951107 cites W2771040910 @default.
- W2944951107 cites W2886761427 @default.
- W2944951107 cites W2896463356 @default.
- W2944951107 cites W2898437582 @default.
- W2944951107 doi "https://doi.org/10.30895/2312-7821-2019-7-1-15-22" @default.
- W2944951107 hasPublicationYear "2019" @default.
- W2944951107 type Work @default.
- W2944951107 sameAs 2944951107 @default.
- W2944951107 citedByCount "4" @default.
- W2944951107 countsByYear W29449511072021 @default.
- W2944951107 countsByYear W29449511072022 @default.
- W2944951107 countsByYear W29449511072023 @default.
- W2944951107 crossrefType "journal-article" @default.
- W2944951107 hasAuthorship W2944951107A5003511699 @default.
- W2944951107 hasAuthorship W2944951107A5010363824 @default.
- W2944951107 hasAuthorship W2944951107A5015370048 @default.
- W2944951107 hasAuthorship W2944951107A5027329850 @default.
- W2944951107 hasAuthorship W2944951107A5033713993 @default.
- W2944951107 hasAuthorship W2944951107A5034671511 @default.
- W2944951107 hasAuthorship W2944951107A5046513164 @default.
- W2944951107 hasAuthorship W2944951107A5048153783 @default.
- W2944951107 hasAuthorship W2944951107A5054603859 @default.
- W2944951107 hasBestOaLocation W29449511071 @default.
- W2944951107 hasConcept C126322002 @default.
- W2944951107 hasConcept C177713679 @default.
- W2944951107 hasConcept C197636746 @default.
- W2944951107 hasConcept C197934379 @default.
- W2944951107 hasConcept C2776364478 @default.
- W2944951107 hasConcept C2777589142 @default.
- W2944951107 hasConcept C2778524551 @default.
- W2944951107 hasConcept C2779609412 @default.
- W2944951107 hasConcept C2780035454 @default.
- W2944951107 hasConcept C57658597 @default.
- W2944951107 hasConcept C60644358 @default.
- W2944951107 hasConcept C71924100 @default.
- W2944951107 hasConcept C86803240 @default.
- W2944951107 hasConcept C98274493 @default.
- W2944951107 hasConceptScore W2944951107C126322002 @default.
- W2944951107 hasConceptScore W2944951107C177713679 @default.
- W2944951107 hasConceptScore W2944951107C197636746 @default.
- W2944951107 hasConceptScore W2944951107C197934379 @default.
- W2944951107 hasConceptScore W2944951107C2776364478 @default.
- W2944951107 hasConceptScore W2944951107C2777589142 @default.
- W2944951107 hasConceptScore W2944951107C2778524551 @default.
- W2944951107 hasConceptScore W2944951107C2779609412 @default.
- W2944951107 hasConceptScore W2944951107C2780035454 @default.
- W2944951107 hasConceptScore W2944951107C57658597 @default.
- W2944951107 hasConceptScore W2944951107C60644358 @default.
- W2944951107 hasConceptScore W2944951107C71924100 @default.
- W2944951107 hasConceptScore W2944951107C86803240 @default.
- W2944951107 hasConceptScore W2944951107C98274493 @default.
- W2944951107 hasIssue "1" @default.
- W2944951107 hasLocation W29449511071 @default.
- W2944951107 hasOpenAccess W2944951107 @default.
- W2944951107 hasPrimaryLocation W29449511071 @default.
- W2944951107 hasRelatedWork W2025414842 @default.
- W2944951107 hasRelatedWork W2092246656 @default.
- W2944951107 hasRelatedWork W2153994797 @default.
- W2944951107 hasRelatedWork W2790501341 @default.
- W2944951107 hasRelatedWork W2944951107 @default.
- W2944951107 hasRelatedWork W3113386111 @default.
- W2944951107 hasRelatedWork W3137416947 @default.
- W2944951107 hasRelatedWork W4282585499 @default.
- W2944951107 hasRelatedWork W2186394847 @default.
- W2944951107 hasRelatedWork W2398119912 @default.
- W2944951107 hasVolume "7" @default.
- W2944951107 isParatext "false" @default.
- W2944951107 isRetracted "false" @default.
- W2944951107 magId "2944951107" @default.
- W2944951107 workType "article" @default.